We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TLS:ASXTelstra Group Limited Analysis

Data as of 2026-06-06 - not real-time

A$4.97

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Telstra’s share price of AUD 4.97 sits below its 20‑day (5.28) and 50‑day (5.32) simple moving averages, indicating short‑term weakness, while the RSI of 25 flags an oversold condition that could spark a bounce toward the support level of AUD 4.89. The MACD remains in a bearish alignment, suggesting lingering downside pressure despite the recent increase in trading volume. Valuation metrics are mixed: a trailing P/E of 24.9 far exceeds the industry average of 16.99, and the DCF‑derived fair value of AUD 3.11 is well below the current price, pointing to an overvalued market stance. However, analysts’ median target of AUD 5.40 implies modest upside of roughly 9%, and the stock offers an attractive 4.23% dividend yield that appeals to income‑focused investors. The balance sheet is strained, with a debt‑to‑equity ratio over 119% and cash covering only a fraction of total debt, raising concerns about the sustainability of the near‑full payout ratio of 96%. Recent broker downgrades add a negative sentiment layer, while opinion pieces highlight the dividend’s allure, leaving the near‑term outlook contingent on whether the price can recover from its technical lows without further rating cuts.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI indicating oversold conditions
  • Proximity to technical support at AUD 4.89
  • Recent broker downgrades increasing downside risk

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Analyst median target price suggesting modest upside
  • High dividend yield attracting income investors
  • Elevated debt levels limiting financial flexibility

Long Term

> 3 years
Cautious
Model confidence: 4/10

Key Factors

  • Unsustainable dividend payout ratio near 96%
  • Overvaluation relative to peers (high P/E, low DCF)
  • Limited revenue growth and heavy leverage

Key Metrics & Analysis

Financial Health

Revenue Growth0.30%
Profit Margin9.80%
P/E Ratio24.8
ROE14.75%
ROA5.85%
Debt/Equity119.14
P/B Ratio4.2
Op. Cash FlowA$7.8B
Free Cash FlowA$3.9B
Industry P/E17.0

Technical Analysis

TrendNeutral
RSI25.3
SupportA$4.89
ResistanceA$5.58
MA 20A$5.28
MA 50A$5.32
MA 200A$5.03
MACDBearish
VolumeIncreasing
Fear & Greed Index83.02

Valuation

Fair ValueA$3.11
Target PriceA$5.27
Upside/Downside5.97%
GradeOvervalued
TypeValue
Dividend Yield4.23%

Risk Assessment

Beta-0.02
Volatility16.66%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.